1. Home
  2. Directory
  3. Texas
  4. Plano
  5. Surgery
  6. NPI Profile
  7. Prescriptions 1164518288

BETH VANDERHOFF ANGLIN M.D.
Prescription History 1164518288
Surgery - Surgical Oncology in Plano, TX


Quality Rating: 75 out of 100 score

NPI Status: Active since October 05, 2006

Contact Information

3801 W 15TH ST
BLDG A, SUITE 210
PLANO, TX
ZIP 75075
Phone: (214) 501-5427
Fax: (214) 501-5429

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BETH VANDERHOFF ANGLIN M.D., an active Surgical Oncology specialist practicing in Plano, TX. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 97 documented patient claims. Among these therapy options, the most frequently utilized medication is Tramadol Hcl, which accounts for 52 claims alone.

Medication Index

L
T
No matching medications currently found on file.

Letrozole

Generic Formulation: LetrozoleSpecialty: General Surgery
Provider Metrics Summary
Total Claims 25
30-Day Fills 49.0
Days Supply 1,470
TX State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills128.1
Peer Average Days Supply3,830
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.1% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $487.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.51

State Avg Cost Per Claim

$27.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: General Surgery
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
TX State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills88.8
Peer Average Days Supply2,658
Conservative Utilization

This provider writes prescriptions for this formulation 47.4% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $383.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.20

State Avg Cost Per Claim

$34.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: General Surgery
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 295
TX State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills63.6
Peer Average Days Supply1,282
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $127.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.45

State Avg Cost Per Claim

$7.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BETH VANDERHOFF ANGLIN M.D. provides transparency into local medical care patterns within Plano, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Surgical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.